ioGlutamatergic Neurons MAPT P301S homozygous - Human iPSC derived cells available to order.
Wild type ioGlutamatergic Neurons (ab303447) form the genetically matched control for the ioGlutamatergic Neurons MAPT P301S homozygous disease model.
Images
Key facts
- Species or organism
- Human
- Form
- Liquid
Recommended products
ioGlutamatergic Neurons MAPT P301S homozygous - Human iPSC derived cells available to order.
Wild type ioGlutamatergic Neurons (ab303447) form the genetically matched control for the ioGlutamatergic Neurons MAPT P301S homozygous disease model.
Key facts
- Species or organism
- Human
- Form
- Liquid
- Concentration
Cell culture
- Biosafety level
- EU: 1 US: 1
- Gender
- Male
Handling procedures
- Culture medium
- Refer to protocol booklet
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
Wild type ioGlutamatergic Neurons (ioGlutamatergic Neurons WT (isogenic control) - Human iPSC derived cells ab303447) form the genetically matched control for the ioGlutamatergic Neurons MAPT P301S homozygous disease model. This physiologically-relevant isogenic pairing offers a a rapidly maturing, consistent and scalable isogenic system to study frontotemporal dementia (FTD).
ioGlutamatergic Neurons MAPT P301S homozygous are ioGlutamatergic Neurons carrying a genetically engineered P301S mutation in the MAPT gene, encoding the tau protein. ioGlutamatergic Neurons MAPT P301S homozygous have been reprogrammed from human iPSCs using opti-oxTM technology, a precise reprogramming technology.
Human stem cells, within days, convert consistently into mature, functional glutamatergic neurons providing a high-quality human model for the study of FTD.
ioGlutamatergic Neurons MAPT P301S homozygous express pan-neuronal and glutamatergic markers TUBB3, MAP2 and VGLUT2 by day 11.
This disease model offers a fast and easy-to-use system for investigations into the impact of gene function on disease progression against an isogenic control.
A heterozygous disease model is also available (ioGlutamatergic Neurons MAPT P301S heterozygous - Human iPSC derived cells ab307784).
In partnership with bit.bio
Karyotype: Normal
Seeding Density: 30,000 cells/cm2
Seeding compatibility: 6-, 12-, 24-, 48-, 96- and 384-well compatible
Quality control: ICC and gene expression analysis
Research applications: Academic research, Drug development, Neurotoxicology, Genetic screening (e.g. CRISPR screening).
Please note, these iPSC-derived glutamatergic neurons preferentially express the 3R MAPT transcript. Total MAPT in wildtype and MAPT P301S heterozygous and homozygous ioGlutamatergic Neurons is predominantly from 3R MAPT transcript and expression of the 4R MAPT transcript is at a low level, comparable to that of the housekeeping gene, HMBS.
This product is subject to limited use licenses from iPS Academia Japan Inc, TET Systems GmbH, ERS Genomics Limited and Sigma-Aldrich Co. LLC and is developed with Bit Bio patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
We will provide viable cells that proliferate on revival.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
4 product images
RT-PCR - ioGlutamatergic Neurons MAPT P301S homozygous - Human iPSC derived cells (ab307783)
Gene expression analysis demonstrates that at day 11, ioGlutamatergic Neurons MAPTP301S/P301S (MAPT P301S/P301S) and the wild type isogenic control (WT) lack the expression of pluripotency makers (NANOG and OCT4) whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR. Data is shown relative to the parental hiPSC control (iPSC Control), normalised to HMBS. Data represents day 11 post-revival samples; n=2 biological replicates.
RT-PCR - ioGlutamatergic Neurons MAPT P301S homozygous - Human iPSC derived cells (ab307783)
RT-qPCR analysis demonstrates similar expression level of the MAPT gene in both wild type ioGlutamatergic Neurons (WT) and ioGlutamatergic Neurons MAPTP301S/P301S (MAPT P301S/P301S) at day 11 post-revival (n=2 replicates). cDNA samples of the parental iPSC line (iPSC Control) were included as a reference.
Functional Studies - ioGlutamatergic Neurons MAPT P301S homozygous - Human iPSC derived cells (ab307783)
ioGlutamatergic Neurons MAPTP301S/P301S mature rapidly and form structural neuronal networks over 11 days, when compared to the isogenic control. Day 1 to 11 post thaw.
100X magnification.
Immunocytochemistry/ Immunofluorescence - ioGlutamatergic Neurons MAPT P301S homozygous - Human iPSC derived cells (ab307783)
Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons MAPTP301S/P301S compared to the isogenic control. 100X magnification.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com